Clinical Trials Logo

Diabetic Foot Infection clinical trials

View clinical trials related to Diabetic Foot Infection.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04289948 Withdrawn - Diabetes Clinical Trials

Assessing the Efficacy of Anti-staphylococcal Phages in the Management of Infected Foot Ulcers in Diabetes

PDFI
Start date: March 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Work Package 1: Observational cohort pilot safety study Work Package 2: Randomised, double-blind, placebo controlled pilot study Work Package 3: Observer-blind pilot RCT

NCT ID: NCT03354806 Withdrawn - Neuropathic Pain Clinical Trials

Peripheral Analgesia in Painful Diabetic Neuropathy

DIALOXY
Start date: June 2018
Phase: N/A
Study type: Interventional

Chronic obliterative arteriopathy of the inferior limbs is a frequent condition observed in diabetics. The later stages induce pain at rest and trophic disorders (ulcer, gangrene) that lead to chronic limb ischemia. Without possible surgical revascularization ,pain management and tissue healing are used to avoid amputation. Prevalence of diabetes is twice higher in Reunion Island than in metropolitan France. As a consequence, the rate co-morbobidities, such as chronic obliterative arteriopathy of the inferior limbs, is also increases. This study compares the efficiency of two analgesic treatments in diabetics with forefoot injuries.

NCT ID: NCT03296436 Withdrawn - Diabetic Foot Ulcer Clinical Trials

A Pilot Study to Assess the Efficacy of NEOX® CORD 1K® in the Treatment of Complex Diabetic Wounds

Start date: January 2020
Phase: Early Phase 1
Study type: Interventional

Patients presenting to Johns Hopkins with a diabetic ulcer classified by the UT Grade 2 or 3 who meet all of the inclusion and none exclusion criteria and give their informed consent, will receive an application of NEOX CORD 1K in addition to standard of care procedures. Those patients will be seen in follow-up at weekly visits until the wound closes and epithelize, achieving complete closure. Subjects that do not achieve complete ulcer closure prior to or at the end of the 16 treatment weeks will exit the study.